New FDA-Approved Treg Therapy to Reduce Chronic GVHD After Allogeneic HSCT.

A centrally manufactured allograft therapy significantly reduces moderate-to-severe chronic GVHD and non-relapse mortality in allogeneic HSCT patients, with no increase in relapse or infection.

• Why it matters: Chronic GVHD remains a major complication limiting the success of allogeneic hematopoietic stem cell transplantation, and effective, safe therapies are urgently needed to improve patient outcomes.
• What they did: The phase 3 trial tested a defined allograft product in a multicenter, randomized setting, demonstrating its ability to promote immune regulation and tolerance without compromising graft-versus-leukemia effects.
• The result: The therapy’s success suggests it can be further optimized and programmed, paving the way for advanced immune reconstitution strategies to enhance transplant success and patient survival.